Key result
Immunosuppressive therapy curbs ventricular arrhythmias and troponin release in pediatric arrhythmogenic cardiomyopathy.
Why the study?
Immunosuppressive therapy application in childhood-onset arrhythmogenic inflammatory cardiomyopathy with recurrent drug-refractory ventricular arrhythmias was not previously reported.
Case Report (n=1)
Hypothesis-generating in pediatric arrhythmogenic cardiomyopathy; leaves open need for controlled trials before any practice change.
We present, to our knowledge, the first case of immunosuppressive therapy (IST) application in a 12-year-old child with arrhythmogenic inflammatory cardiomyopathy resulting from the overlap between autoimmune myocarditis and primary arrhythmogenic cardiomyopathy. Indication to off-lable IST was compelling, because of recurrent drug-refractory ventricular arrhythmias (VAs). We show that IST was feasible, safe, and effective on multiple clinical endpoints, including symptoms, VA recurrences, and T-troponin release. Remarkably, all diagnostic and therapeutic strategies were worked out by a dedicated multidisciplinary team, including specialized pediatric immunologists.
No takes yet. Share an insight, caveat, or question.
Peretto et al. (2020) conducted a case report in Arrhythmogenic inflammatory cardiomyopathy (n=1). Immunosuppressive therapy (IST) was evaluated on Multiple clinical endpoints, including symptoms, VA recurrences, and T-troponin release. Immunosuppressive therapy was feasible, safe, and effective at reducing symptoms, ventricular arrhythmia recurrences, and T-troponin release in a 12-year-old child with arrhythmogenic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: